Drug intelligence / Profile preview

Universal Cancer Immune-Enhancer (VLP+MCT)

Development stage: Preclinical
Lead developer: DeepVax
Modality: Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration: Parenteral

Overview

**Universal Cancer Immune-Enhancer (VLP+MCT)** is a preclinical DeepVax therapeutic cancer-vaccine immune-enhancement platform combining virus-like particles with microcrystalline tyrosine. The VLP component is intended to promote rapid lymphatic trafficking and antigen-specific immune priming, while microcrystalline tyrosine forms a local depot that prolongs immune exposure. In a murine melanoma model, a VLP-based vaccine formulated with microcrystalline tyrosine enhanced antigen-specific cytotoxic CD8-positive T-cell responses and tumor protection compared with alum. DeepVax states that the VLP plus microcrystalline tyrosine immune-enhancer has also shown promising results in horses and is being prepared for translation to human applications.

Other names: Universal Cancer Immune-Enhancer (VLP+MCT)

Beyond the preview

Go deeper on Universal Cancer Immune-Enhancer (VLP+MCT).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Universal Cancer Immune-Enhancer (VLP+MCT).

Explore the full profile